FDA Issues Warning to Novo Nordisk Over Ozempic and Wegovy Reporting

Concerns raised over delayed reporting of adverse events, including deaths, linked to popular weight loss drugs.

Mar. 14, 2026 at 3:19am

Got story updates? Submit your updates here. ›

The U.S. Food and Drug Administration (FDA) has issued a warning letter to Novo Nordisk, the manufacturer of the weight loss drugs Ozempic and Wegovy, regarding the company's failure to properly report serious and unexpected adverse events associated with the medications. The FDA inspection found issues with Novo Nordisk's timely reporting of three deaths, including one suicide, as well as a case of suicidal ideation. The agency also cited concerns over the company dismissing adverse events as unrelated to the drugs without proper investigation.

Why it matters

The FDA's action signals increased regulatory scrutiny of the rapidly growing GLP-1 receptor agonist (GLP-1RA) market, which includes Ozempic and Wegovy. These medications have seen surging demand for their effectiveness in weight loss, raising concerns about the thoroughness of post-market surveillance to identify and address potential safety issues as usage increases.

The details

The FDA's warning letter, dated March 5, 2026, stemmed from an inspection conducted in 2025 at Novo Nordisk's U.S. headquarters. Investigators found that the company failed to adequately report serious and unexpected adverse events, including deaths and instances of suicidal ideation. Specifically, the FDA cited issues with the timely reporting of three deaths, including one suicide, and a case of suicidal thoughts, some of which were over 1,000 days late. The agency also noted that Novo Nordisk sometimes dismissed serious adverse events as being unrelated to the medication without proper investigation.

  • The FDA inspection took place in 2025.
  • The warning letter was issued on March 5, 2026.

The players

Novo Nordisk

A pharmaceutical company that manufactures the weight loss drugs Ozempic and Wegovy.

Dr. David Burrow

Director of the Office of Scientific Investigations at the FDA.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

What’s next

The FDA's action could lead to more frequent and rigorous inspections of Novo Nordisk and other GLP-1RA manufacturers. It may also prompt a reevaluation of the risk-benefit profile of these drugs, potentially influencing prescribing guidelines and patient education materials.

The takeaway

The FDA's warning to Novo Nordisk is part of a broader trend of increased scrutiny for drugs with rapidly growing popularity and significant public health implications. This case highlights the importance of robust post-market surveillance and timely reporting of adverse events to ensure the safety and efficacy of medications, especially as usage continues to surge.